Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Effective treatment options for disorders of consciousness (DoC) remain limited, and available interventions show heterogeneous efficacy. To date, limited evidences support the use of amantadine and transcranial direct current stimulation in this population.
Bloodletting puncture (BP) at the hand twelve Jing-Well points (HTWPs) has been traditionally used in China as an empirical therapy for DoC; however, its efficacy has not been established by robust clinical evidence. Transcutaneous electrical acupoint stimulation (TEAS) provides a modern, noninvasive alternative for acupoint stimulation. The Wells-DoC trial, a multicenter, randomized, controlled, open-label study with blinded endpoint assessment, provided preliminary evidence that TEAS applied at the hand twelve Jing-Well points was associated with a numerically higher proportion of consciousness improvement in patients with DoC, although the difference did not reach statistical significance. These findings support the need for further evaluation in an adequately powered randomized controlled trial.
The Wells-DoC II trial is a multicenter, randomized, controlled, double-blind clinical trial designed to evaluate the efficacy and safety of TEAS at the twelve Jing-Well points of the hand in patients with DoC. The primary objective of the Wells-DoC II trial is to determine whether TEAS applied at the twelve Jing-Well points of the hand improves consciousness in adults with DoC. The primary endpoint is the proportion of patients achieving consciousness improvement after 14 consecutive days of treatment, compared between the TEAS group and the sham stimulation (placebo control) group.
The secondary objectives are to assess the effects of TEAS versus sham stimulation on: (1) changes in Coma Recovery Scale-Revised (CRS-R) scores at 7 and 14 days; (2) change in ABCD model classification at day 14; and (3) functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 and 6 months after enrollment.
A total of 160 patients will be recruited over a 28-month period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Transcutaneous electrical stimulation group | Experimental | Patients randomized to the treatment group will receive transcutaneous electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC. |
|
| Sham electrical stimulation group | Sham Comparator | Patients randomized to the Sham electrical stimulation group will receive sham electrical acupoint stimulation at hand twelve jing-well points for 14 consecutive days, twice a day, combined with conventional treatment or rehabilitation for patients with DoC. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Transcutaneous electrical stimulation | Device | Transcutaneous electrical acupoint stimulation at hand twelve jing-well points |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of consciousness improvement after 14 consecutive days of treatment | The primary effectiveness outcome was the proportion of patients with consciousness improvement after 14 consecutive days of treatment, wherein improvements from unresponsive wakefulness syndrome (UWS)/vegetative state (VS) to minimally conscious state (MCS) or emergence from minimally conscious state (EMCS), from MCS minus (MCS-) to MCS plus (MCS+) or EMCS, or from MCS+ to EMCS signify a consciousness improvement. Diagnoses of UWS/VS, MCS (minus or plus) and EMCS were determined based on the presence of specific Coma Recovery Scale-Revised (CRS-R) subscale items, assessed by a trained neurologist. The hierarchical order of consciousness levels from worst to best is UWS/VS, MCS-, MCS+, and EMCS. | 14 days after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment | CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. | 7 days after treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wen Jiang, Dr. | Contact | +86 29 84771319 | jiangwen@fmmu.edu.cn | |
| Zhirong Fan, Dr. | Contact | +86 29 84771319 | fzr1601@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xijing Hospital | Xi'an | Shaanxi | China |
NOT YET DECIDED
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003244 | Consciousness Disorders |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004561 | Transcutaneous Electric Nerve Stimulation |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D012046 | Rehabilitation |
Not provided
Not provided
Not provided
Not provided
Not provided
All study members are blinded to randomization except the following: electrical stimulation operators in each investigation site. Electrical stimulation operators are independent of all other components of the trial and are responsible for participant randomization as well as the administration of both active TEAS and sham interventions. Consequently, they are aware of treatment allocation. To minimize bias, they will not be involved in outcome assessment, data collection beyond the intervention procedures, or statistical analysis, and will be required to maintain strict confidentiality regarding group assignments throughout the study.
| Sham electrical stimulation | Device | Sham electrical acupoint stimulation at hand twelve jing-well points |
|
| Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 7 days of treatment |
CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance. |
| 7 days after treatment |
| Changes in Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment | CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. | 14 days after treatment |
| Changes in sub scale of Coma Recovery Scale-Revised (CRS-R) scores after 14 days of treatment | CRS-R is composed of six subscales: auditory function, visual function, motor function, oromotor function, communication ability, and arousal level. CRS-R score ranges from 0 to 23, with higher scores mean a better outcome. Each sub scale consists of multiple hierarchically organized questions, with higher scores indicating greater performance. | 14 days after treatment |
| Changes in ABCD model classification after 14 days of treatment | This model classifies the power spectrum of resting-state EEG data into four categories: A, B, C, and D. Type A exhibit a power spectrum peak in the delta range (0-4 Hz), indicative of a completely disconnected thalamocortical network. Type B shows a primary power spectrum peak in the theta range (4-8 Hz), reflecting a severely disconnected thalamocortical network. Type C exhibits power spectrum peaks in both the theta (4-8 Hz) and beta (13-24 Hz) ranges, indicative of a moderately disconnected thalamocortical network. Type D shows power spectrum peaks in the alpha (8-13 Hz) and beta ranges, representing a fully intact thalamocortical network. | 14 days after treatment |
| Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 3 months after enrollment | Functional outcomes were assessed at 3 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes). | 3 months after enrollment |
| Functional outcomes measured by the Glasgow Outcome Scale-Extended (GOSE) at 6 months after enrollment | Functional outcomes were assessed at 6 months after enrollment using the Glasgow Outcome Scale-Extended (GOSE; range 1-8, where higher scores indicate better functional outcomes). | 6 months after enrollment |
| Incidence of adverse events during 6 months after enrollment | The safety outcome was the incidence of adverse events during 6 months after enrollment. | 6 months after enrollment |
| Incidence of severe adverse events during 6 months after enrollment | The safety outcome was the incidence of severe adverse events during 6 months after enrollment. | 6 months after enrollment |
| Incidence of adverse events prespecified for transcutaneous electrical stimulation during treatment | The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention. | from the first treatment on Day 1 to the completion of the last treatment on Day 14 |
| Incidence of severe adverse events prespecified for transcutaneous electrical stimulation during treatment | The following adverse events are prespecified for transcutaneous electrical stimulation applied to the twelve Jing-Well points of the hand, including treatment intolerance: manifested as observable distress responses during stimulation, (e.g., painful facial expressions, moaning, crying, or involuntary head movements); local adverse effects: skin infection (e.g., redness, swelling, suppuration), subcutaneous ecchymosis, and skin burns (e.g., blistering or eschar formation) at stimulation sites; and systemic adverse effects: epileptic seizures temporally associated with the intervention. Serious adverse events (SAEs) are defined as any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity | from the first treatment on Day 1 to the completion of the last treatment on Day 14 |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D000698 |
| Analgesia |
| D000760 | Anesthesia and Analgesia |